Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best growth stocks under $20 to buy. On May 5, Adaptive Biotechnologies reported strong Q1 2026 results, with total revenue reaching $70.9 million, a 35% increase year-over-year. The company’s Minimal Residual Disease/MRD business served as the primary growth driver, accounting for 95% of total revenue and experiencing a 53% surge compared to Q1 2025. Test volume for its flagship clonoSEQ product rose 41% to 32,595 tests.

The company reduced its net loss to $20.0 million, down from $29.8 million in Q1 2025, and its non-GAAP Adjusted EBITDA loss narrowed to $2.5 million. Supported by this performance and $9 million in recognized regulatory milestone revenue, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) raised its full-year 2026 MRD revenue guidance to a range of $260 to $270 million.

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

With $237.2 million in cash, cash equivalents, and marketable securities as of March 31, the company remains focused on its growth strategy. Leadership emphasized that accelerating adoption across clinical testing and drug development positions the firm to sustain its market leadership and continue generating long-term value.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is involved in the development of an immune medicine platform, with its services and products including immunoSEQ, clonoSEQ, cellular therapy, and vaccines.

While we acknowledge the risk and potential of ADPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ADPT and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1